Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Open-Label, Active-Controlled, Multicenter Study to Evaluate the Safety and Serum Phosphorus Lowering Effect of AP-306 in Chronic Kidney Disease Patients Receiving Maintenance Hemodialysis With Hyperphosphatemia

Next Previous
X
Search
Trial Profile

A Phase 2, Randomized, Open-Label, Active-Controlled, Multicenter Study to Evaluate the Safety and Serum Phosphorus Lowering Effect of AP-306 in Chronic Kidney Disease Patients Receiving Maintenance Hemodialysis With Hyperphosphatemia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Jan 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs EOS 789 (Primary) ; Sevelamer
  • Indications Hyperphosphataemia; Renal failure
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Shanghai Alebund Pharmaceuticals

    • Most Recent Events

    • 07 Jan 2025 According to an Alebund Pharmaceuticals media release, company announced the closing of RMB 550 million in Series C financing. This round of financing will support the conduct of US/China phase 2 study for the first-in-class pan phosphate transporter inhibitor AP306.
    • 08 Jan 2024 Status changed from recruiting to completed.
    • 13 Dec 2023 According to Alebund Pharmaceuticals Media Release,the study involved 11 investigational sites in China, led by Dr. Li Wang from Sichuan Provincial People's Hospital.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top